FOI Request Shows Significantly Higher Reports of Serious Adverse Events and Deaths in Moderna Clinical Trial Participants Who Took the mRNA Jab Compared to the Placebo Group.

THE CANADIAN INDEPENDENT

JUL 22, 2023



The FDA has recently released a massive FOI request that comprises nearly 15,000 pages. It was made public only after a judge ruled in favor of the requester, who took the FDA to court over its refusal to release Moderna's mRNA Covid jab clinical trial documents.

This clinical trial was Moderna's first 2-dose trial of its mRNA-1273 Covid-19 vaccine conducted back in 2020.

One interesting part of Moderna's mRNA-1273 Covid-19 vaccine clinical trial documents is the 218 pages dedicated to serious adverse events (SAEs) reported during follow up after the jabs. These pages categorize the participants into three groups: those who took placebo shots, those who took a placebo and then an mRNA shot, and those who solely took 2 doses of the mRNA shot.

In the placebo group, there were only 5 pages with 7 participants listed as having a serious adverse event. These are pages 2 to 6.

However, when examining the participants flagged for a serious adverse event in the placebo-mRNA jab or solely the 2 doses of the mRNA jab category, there are hundreds of pages with hundreds of participants. These are pages 7 to 208.

Regarding deaths in the clinical trial reports, there was only one death in the placebo group, three deaths in the placebo-mRNA group, and 8 deaths in those who solely took 2 doses of the mRNA jab. All participants were negative for Covid-19 at the time of their death.

The deaths in the 2-dose mRNA participants included cardiac disorders, nervous system issues, pulmonary embolism, stroke, and gastrointestinal bleed. I listed a few of them below.



Treatment Group: mRNA-1273

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solicited AR	Sev. [1]	SAE/ Criteria [2]	Relation-ship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US3302465; Age (years): 69; Sex: M; Race: BLACK OR AFRICAN AMERICAN; Risk Factors for Severe COVID-19[4]: CL/D; Height (cm): 179.1; Weight (kg): 93.2; BMI (kg/m^2): 29.1; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 29SEP2020:15:06:00; Follow-up Days after 1st Dose: 123; Dose 2 Date/Time: 27OCT2020:10:40:00; Follow-up Days after 2nd Dose: 95							
Cardiac disorders/ Myocardial infarction/ MYOCARDIAL INFARCTION	2021-01-29 (95)/ 2021-01-29 (95)	Yes/ Yes/ No	5	Yes/1	NR/ NR	NOT APPLICABLE/ NONE	FATAL

Subject ID: US3312006; Age (years): 62; Sex: M; Race: WHITE; Risk Factors for Severe COVID-19[4]:; Height (cm): 180.3; Weight (kg): 75.0; BMI (kg/m²): 23.1; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 10AUG2020:12:54:00; Follow-up Days after 1st Dose: 212; Dose 2 Date/Time: 07SEP2020:10:36:00; Follow-up Days after 2nd Dose: 184

Cardiac disorders/ Acute myocardial infarction/ ACUTE MYOCARDIAL INFARCTION	2021-03-09 (184)/ 2021-03-09 (184)	Yes/ No/ No	5	Yes/1	NR/ NR	NOT APPLICABLE/ NONE	FATAL

Subject ID: US3412151; Age (years): 71; Sex: M; Race: WHITE; Risk Factors for Severe COVID-19[4]:; Height (cm): 171.5; Weight (kg): 114.0; BMI (kg/m²): 38.8; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 06AUG2020:10:35:00; Follow-up Days after 1st Dose: 240; Dose 2 Date/Time: 03SEP2020:08:03:00; Follow-up Days after 2nd Dose: 212

Vascular disorders/ Aortic stenosis/ WORSENING OF AORTIC STENOSIS	2021-02-05 (156)/ Ongoing	Yes/ Yes/ No	2	Yes/3 (2021-03-31/)/6	NR/ NR	NOT APPLICABLE/ CONCOMITANT PROCEDURE	NOT RECOVERED/ NOT RESOLVED
Nervous system disorders/ Cerebrovascular accident/ STROKE	2021-03-31 (210)/ 2021-04-02 (212)	Yes/ Yes/ No	5	Yes/1/3 (2021-03-31/)/4/6	NR/ NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	FATAL

Subject ID: US3702046; Age (years): 49; Sex: M; Race: BLACK OR AFRICAN AMERICAN; Risk Factors for Severe COVID-19[4]: SO; Height (cm): 180.7; Weight (kg): 144.3; BMI (kg/m²): 44.2; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 25SEP2020:10:34:00; Follow-up Days after 1st Dose: 166; Dose 2 Date/Time: 23OCT2020:10:08:00; Follow-up Days after 2nd Dose: 138

Respiratory, thoracic and mediastinal disorders/ Pulmonary embolism/ PULMONARY EMBOLISM	2021-03-01 (130)/ 2021-03-09 (138)	Yes/ Yes/ No	5	Yes/1/2/3 (2021-02-26/ 2021-03-09)	NR/ NR	NOT APPLICABLE/ CONCOMITANT MEDICATION	FATAL
Cardiac disorders/ Pulseless electrical activity/ PULSELESS ELECTRICAL ACTIVITY	2021-03-09 (138)/ 2021-03-09 (138)	Yes/ Yes/ No	5	Yes/1/2	NR/ NR	NOT APPLICABLE/ NONE	FATAL

Additionally, in the placebo-mRNA and 2 dose mRNA group there was one report of sudden death and one report of a participant listed as dying as a result of head trauma from a fall.

Listing 16.2.7.9.3
Serious Adverse Events in Open-Label Phase
Safety Set

Treatment Group: mRNA-1273

System Organ Class/ Preferred Term/ Verbatim	Start Date and Time (Relative Day)/ End Date and Time (Relative Day)	TEAE/ MAAE/ Solicited AR	Sev. [1]	SAE/ Criteria [2]	Relationship to IP/SP [3]	Action Taken with IP/ Other Action Taken	Outcome
Subject ID: US3202375; Age (years): 56; Sex: F; Race: WHITE; Risk Factors for Severe COVID-19[4]:; Height (cm): 164.0; Weight (kg): 69.9; BMI (kg/m²): 26.0; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 01SEP2020:10:54:00; Follow-up Days after 1st Dose: 216; Dose 2 Date/Time: 05OCT2020:09:31:00; Follow-up Days after 2nd Dose: 182							
General disorders and administration site conditions/ Sudden death/	2021-04-04 (182)/ 2021-04-04 (182)	Yes/ Yes/ No	5	Yes/1	NR/ NR	NOT APPLICABLE/ NONE	FATAL



SUDDEN DEATH (UNKNOWN CAUSE)

Subject ID: US3572251; Age (years): 41; Sex: M; Race: WHITE; Risk Factors for Severe COVID-19[4]: D; Height (cm): 172.7; Weight (kg): 100.9; BMI (kg/m²): 33.8; Baseline SARS-CoV-2 Status: Negative; Baseline RT-PCR: Negative; Baseline Elecsys SARS-CoV-2 Nucleocapsid bAb: Negative; Dose 1 Date/Time: 10SEP2020:12:16:00; Follow-up Days after 1st Dose: 206; Dose 2 Date/Time: 06OCT2020:13:23:00; Follow-up Days after 2nd Dose: 180

Injury, poisoning and procedural complications/ Head injury/ HEAD TRAUMA DUE TO FALL	2021-04-03 (180)/ 2021-04-03 (180)	Yes/ Yes/ No	5	Yes/1	NR/ NR	NOT APPLICABLE/ NONE	FATAL

Note: Footnotes are listed on the last page.
Program Path: \\wilbtia\wilbtia01\Moderna MODMRNA1273P301_U\BLA\TLF\11602070903.sas 24JUN2021 06:38

FDA-CBER-2022-908-0013636

Looking at the serious adverse events reported in the placebo-mRNA and those who solely took 2 doses of the mRNA jab, there was a significant number of participants during follow-up who were still recovering or not yet recovered. This group included participants who experienced severe bouts of Covid-19, cardiac issues, other infections including RSV, eye issues, gastrointestinal disorders, tooth decay, sepsis, musculoskeletal and connective tissue disorders, renal and urinary disorders, nervous system disorders, skin and subcutaneous tissue disorders, pancreatic cancer, Bells Palsy, Shingles and many others.

The Canadian Independent will continue to go through the FOI documents and bring you any other relevant findings.

7 Likes · 1 Restack

1 Comment

Write a comment...

MEME Jul 22